A Comprehensive Guide to Pulmonology: Respiratory Assessment Tools and Lung Health

What Is Pulmonology?

Pulmonary diseases are responsible for approximately 4 million deaths annually worldwide; COPD alone kills 3.2 million people per year, making respiratory disease the third leading cause of death globally (WHO 2020). The respiratory system performs one of the body's most essential functions: the exchange of oxygen and carbon dioxide that sustains every cell. Pulmonology is the medical specialty devoted to the diagnosis and treatment of lung and respiratory diseases. From asthma and chronic obstructive pulmonary disease (COPD) to respiratory failure requiring supplemental oxygen, pulmonary conditions affect hundreds of millions of people worldwide. This guide explains the fundamentals of respiratory medicine, introduces the clinical tools used to assess and manage lung disease, and provides practical information about maintaining lung health.

How Does the Respiratory System Work?

An adult at rest breathes approximately 12–20 times per minute, moving 6–8 liters of air; the 300 million alveoli provide approximately 70 square meters of gas exchange surface—roughly the size of a tennis court. The respiratory system consists of the upper airways (nose, mouth, pharynx, and larynx), the lower airways (trachea, bronchi, and progressively smaller bronchioles), and the lung parenchyma (the alveoli, tiny air sacs where gas exchange occurs). An adult has approximately 300 million alveoli, providing a total surface area for gas exchange of about 70 square meters, roughly the size of a tennis court.

During inhalation, the diaphragm contracts and moves downward, the intercostal muscles expand the rib cage, and negative pressure draws air into the lungs. Oxygen diffuses across the alveolar membrane into the pulmonary capillaries, where it binds to hemoglobin in red blood cells for transport to the tissues. Simultaneously, carbon dioxide, a waste product of cellular metabolism, diffuses from the blood into the alveoli and is exhaled.

This process depends on three factors working in concert: ventilation (the mechanical movement of air in and out of the lungs), diffusion (the transfer of gases across the alveolar-capillary membrane), and perfusion (blood flow through the pulmonary capillaries). Disease can disrupt any or all of these components.

How Is Oxygen Therapy Delivered?

Supplemental oxygen is prescribed to approximately 1 million people in the United States for home use; oxygen toxicity becomes clinically significant at FiO2 above 0.60 maintained for more than 24 hours, making precise delivery calibration essential. Supplemental oxygen is one of the most commonly prescribed therapies in medicine. Understanding how oxygen is delivered and quantified is essential for both clinicians and patients.

The fraction of inspired oxygen (FiO2) represents the concentration of oxygen in the air a person is breathing. Room air has an FiO2 of 0.21, or 21 percent. Supplemental oxygen devices increase the FiO2 above this baseline to varying degrees.

A nasal cannula is the simplest and most commonly used oxygen delivery device. It consists of two small prongs that sit just inside the nostrils and delivers oxygen at flow rates typically ranging from 1 to 6 liters per minute. Use the FiO2 Conversion Calculator to estimate the delivered FiO2 for any oxygen delivery device. As a general approximation, each liter per minute of nasal cannula flow increases the FiO2 by about 3 to 4 percent. Thus, a nasal cannula at 2 liters per minute delivers approximately 28 percent FiO2, at 4 liters per minute approximately 36 percent, and at 6 liters per minute approximately 44 percent. However, the actual FiO2 varies depending on the patient's respiratory rate, tidal volume, and breathing pattern, making these estimates approximate rather than precise.

A simple face mask delivers higher concentrations of oxygen (approximately 35 to 50 percent FiO2) at flow rates of 6 to 10 liters per minute. A minimum flow of 5 to 6 liters per minute is required to prevent rebreathing of exhaled carbon dioxide.

A non-rebreather mask, equipped with a reservoir bag and one-way valves, can deliver FiO2 of approximately 60 to 90 percent at flow rates of 10 to 15 liters per minute. It is used in acute situations where high-concentration oxygen is needed, such as carbon monoxide poisoning, severe trauma, or acute respiratory distress.

A Venturi mask uses a jet-mixing principle to deliver precise, fixed FiO2 concentrations (typically 24, 28, 31, 35, 40, or 50 percent) regardless of the patient's breathing pattern. This precision makes it particularly useful for patients with COPD, where excessive oxygen delivery can suppress respiratory drive and worsen carbon dioxide retention.

High-flow nasal cannula (HFNC) systems can deliver heated, humidified oxygen at flow rates up to 60 liters per minute with FiO2 ranging from 21 to 100 percent. HFNC provides several physiological benefits beyond oxygen delivery, including a small amount of positive airway pressure, reduced work of breathing, and improved clearance of carbon dioxide from the upper airway dead space.

How Long Does an Oxygen Tank Last?

A standard E-cylinder (the most common portable oxygen tank) contains approximately 680 liters of oxygen; at 2 liters per minute flow, this provides roughly 5.7 hours of use—critical information for safe discharge planning. For patients who use portable oxygen tanks for mobility, knowing how long a tank will last at a given flow rate is essential for safety and planning. The duration of an oxygen tank depends on three factors: the tank size (which determines the total volume of oxygen available), the pressure remaining in the tank (measured by a gauge), and the flow rate at which oxygen is being delivered.

The Oxygen Tank Duration Calculator computes how long your supply will last. The formula is: remaining pressure (in PSI) multiplied by the tank conversion factor, divided by the flow rate in liters per minute. Each tank size has a specific conversion factor. For example, a D-cylinder has a factor of 0.16, an E-cylinder (the most common portable size) has a factor of 0.28, and an H-cylinder (used in hospitals) has a factor of 3.14.

For a full E-cylinder with a pressure of 2000 PSI at a flow rate of 2 liters per minute, the calculation would be: 2000 multiplied by 0.28, divided by 2, which equals 280 minutes, or approximately 4 hours and 40 minutes. At 4 liters per minute, the same tank would last about 140 minutes, or approximately 2 hours and 20 minutes.

Patients and caregivers should always plan conservatively and have backup oxygen available, particularly during travel or outings.

How Is Respiratory Failure Assessed?

A P/F ratio below 300 defines acute respiratory failure; below 200 indicates severe acute respiratory distress syndrome (ARDS), which carries a 30-day mortality of approximately 40–45% in ICU populations (LUNG SAFE 2016 study). The ratio of arterial oxygen partial pressure (PaO2) to the fraction of inspired oxygen (FiO2) is one of the most important calculations in critical care medicine. Calculate it instantly with the P/F Ratio Calculator. Known as the P/F ratio, it provides a standardized way to assess the severity of oxygenation impairment regardless of how much supplemental oxygen the patient is receiving.

The PaO2 is measured from an arterial blood gas (ABG) sample and represents the partial pressure of oxygen dissolved in the arterial blood, measured in millimeters of mercury (mmHg). A normal PaO2 on room air is approximately 80 to 100 mmHg.

To calculate the P/F ratio, simply divide the PaO2 by the FiO2 (expressed as a decimal). For example, a patient with a PaO2 of 90 mmHg on room air (FiO2 of 0.21) has a P/F ratio of 90 divided by 0.21, which equals approximately 429. This is normal. A patient with a PaO2 of 80 mmHg on 40 percent oxygen (FiO2 of 0.40) has a P/F ratio of 80 divided by 0.40, which equals 200. This indicates significant oxygenation impairment.

The P/F ratio is central to the Berlin Definition of Acute Respiratory Distress Syndrome (ARDS). Mild ARDS is defined by a P/F ratio of 200 to 300, moderate ARDS by a P/F ratio of 100 to 200, and severe ARDS by a P/F ratio below 100. These categories guide treatment decisions, including the use of prone positioning, neuromuscular blockade, and extracorporeal membrane oxygenation (ECMO) in the most severe cases.

A normal P/F ratio is approximately 400 to 500. Values below 300 indicate significant respiratory impairment, and values below 200 generally indicate the need for intensive care support.

How Is COPD Staged?

COPD affects approximately 300 million people worldwide and is the third leading cause of death globally; it is underdiagnosed in approximately 70% of affected individuals until the disease is already moderately advanced. Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by persistent airflow limitation. It affects an estimated 300 million people worldwide and is the third leading cause of death globally. The primary cause of COPD is tobacco smoking, though occupational dust and chemical exposure, indoor air pollution from biomass fuels, and genetic factors (such as alpha-1 antitrypsin deficiency) also contribute.

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) provides the most widely used framework for classifying COPD severity. The classification has two components: the degree of airflow limitation based on spirometry and an assessment of symptoms and exacerbation risk.

The COPD GOLD Calculator classifies your COPD severity based on post-bronchodilator FEV1. Spirometric classification uses post-bronchodilator FEV1, the volume of air a person can forcefully exhale in one second, expressed as a percentage of the predicted normal value for their age, sex, and height. GOLD 1 (mild) is defined as FEV1 of 80 percent or more of predicted. GOLD 2 (moderate) is FEV1 of 50 to 79 percent of predicted. GOLD 3 (severe) is FEV1 of 30 to 49 percent of predicted. GOLD 4 (very severe) is FEV1 less than 30 percent of predicted. A diagnosis of COPD requires a post-bronchodilator FEV1/FVC ratio of less than 0.70, confirming the presence of persistent airflow limitation.

The GOLD ABE assessment group combines symptom burden (measured by validated questionnaires such as the CAT or mMRC dyspnea scale) with exacerbation history to guide treatment. Group A includes patients with few symptoms and low exacerbation risk. Group B includes patients with more symptoms but low exacerbation risk. Group E includes patients with frequent exacerbations, regardless of symptom burden.

Management of COPD is multimodal and includes smoking cessation (the single most effective intervention for slowing disease progression), inhaled bronchodilators (short-acting and long-acting beta-agonists and antimuscarinics), inhaled corticosteroids (for patients with frequent exacerbations and eosinophilic inflammation), pulmonary rehabilitation (a structured exercise and education program that significantly improves quality of life), and vaccination against influenza, pneumococcus, COVID-19, and respiratory syncytial virus.

How Is Asthma Control Assessed?

Asthma affects approximately 262 million people worldwide and causes approximately 455,000 deaths annually; approximately 50% of asthma patients have poorly controlled disease despite available treatments (WHO 2022). Asthma is a chronic inflammatory airway disease characterized by variable airflow obstruction, bronchial hyperresponsiveness, and symptoms including wheezing, cough, chest tightness, and shortness of breath. Unlike COPD, the airflow obstruction in asthma is typically reversible, either spontaneously or with treatment.

The Asthma Control Test Calculator is a validated, patient-reported questionnaire that assesses how well asthma is controlled over the preceding four weeks. It consists of five questions addressing the frequency of symptoms, the impact of asthma on daily activities, nighttime awakenings due to asthma, use of rescue inhaler, and the patient's own rating of their asthma control. Each question is scored from 1 to 5, with a maximum total score of 25.

A score of 20 to 25 indicates well-controlled asthma. A score of 16 to 19 indicates not well-controlled asthma. A score of 15 or below indicates very poorly controlled asthma. Patients with scores below 20 should discuss their treatment plan with their healthcare provider, as adjustments to controller medications may be needed.

The ACT is useful not only for individual patient management but also for tracking trends over time. A decrease of 3 or more points from a previous score is clinically meaningful and suggests worsening control that warrants evaluation.

What Is the Pack-Year Calculation?

Smoking accounts for approximately 80% of COPD cases and 85% of lung cancer cases; a cumulative exposure above 20 pack-years doubles the risk of significant COPD and increases lung cancer risk 15–25-fold compared to non-smokers. Quantifying a person's lifetime smoking exposure is essential for assessing the risk of smoking-related diseases, including COPD, lung cancer, cardiovascular disease, and many other conditions. The standard unit of measurement is the pack-year.

One pack-year is defined as smoking one pack of cigarettes (20 cigarettes) per day for one year. The Pack-Year Calculator computes your lifetime tobacco exposure. The calculation is straightforward: multiply the number of packs smoked per day by the number of years of smoking. A person who smoked two packs per day for 15 years has a 30 pack-year history. A person who smoked half a pack per day for 40 years has a 20 pack-year history.

Pack-year history directly informs clinical decisions. Current guidelines from the United States Preventive Services Task Force recommend annual low-dose computed tomography (LDCT) lung cancer screening for adults aged 50 to 80 who have a 20 pack-year or greater smoking history and currently smoke or have quit within the past 15 years. This screening has been shown to reduce lung cancer mortality by approximately 20 percent.

Pack-year history also correlates with the risk and severity of COPD. While not every smoker develops COPD, the risk increases substantially with increasing pack-year exposure. Importantly, smoking cessation at any stage provides benefit. Even patients with established COPD experience a slower rate of lung function decline after quitting compared to those who continue to smoke.

What Is Pulmonary Function Testing?

PFTs are among the most informative investigations in respiratory medicine; spirometry alone correctly classifies obstructive versus restrictive disease in approximately 85% of cases, guiding treatment choices for millions of patients annually. Pulmonary function tests (PFTs) are a group of measurements that assess how well the lungs are working. The most common and widely available PFT is spirometry, which measures the volume and speed of air that can be exhaled.

Key spirometric measurements include the Forced Vital Capacity (FVC), which is the total volume of air that can be forcefully exhaled after a maximal inhalation; the Forced Expiratory Volume in one second (FEV1), the volume of air exhaled in the first second of the FVC maneuver; and the FEV1/FVC ratio, which helps distinguish between obstructive and restrictive lung diseases. An FEV1/FVC ratio below the lower limit of normal (or below 0.70 by fixed-ratio criteria) indicates obstructive disease, while a proportionally reduced FVC with a preserved or elevated ratio suggests restrictive disease.

Additional PFTs include lung volume measurements (using body plethysmography or gas dilution techniques), which can confirm restrictive disease by demonstrating reduced total lung capacity, and the diffusing capacity for carbon monoxide (DLCO), which assesses the efficiency of gas transfer across the alveolar-capillary membrane. A reduced DLCO can indicate emphysema, interstitial lung disease, or pulmonary vascular disease.

When to Seek Medical Care for Respiratory Symptoms

Certain respiratory symptoms warrant prompt medical evaluation. These include new or worsening shortness of breath that limits normal activities, chest pain associated with breathing, coughing up blood (hemoptysis), a persistent cough lasting more than three weeks, wheezing or stridor (a high-pitched sound during inhalation that may indicate upper airway obstruction), and signs of respiratory distress including use of accessory muscles (visible neck and chest muscle straining during breathing), inability to speak in full sentences due to breathlessness, or bluish discoloration of the lips or fingertips (cyanosis).

Patients with known COPD or asthma should be familiar with their action plan for exacerbations and know when to escalate care. An exacerbation that does not respond to initial rescue therapy (such as albuterol), worsening breathlessness at rest, or confusion and drowsiness (which may indicate rising carbon dioxide levels) are all indications for emergency evaluation.

Pulmonary medicine continues to advance with new therapies for severe asthma (biologic agents targeting specific inflammatory pathways), improved approaches to COPD management, and evolving understanding of conditions such as interstitial lung disease and pulmonary hypertension. The clinical tools described in this guide, from FiO2 conversion and oxygen tank duration calculations to the P/F ratio, GOLD classification, Asthma Control Test, and pack-year calculation, provide the foundation for understanding and managing respiratory health across a wide range of conditions.